JPWO2024029599A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2024029599A5 JPWO2024029599A5 JP2024513824A JP2024513824A JPWO2024029599A5 JP WO2024029599 A5 JPWO2024029599 A5 JP WO2024029599A5 JP 2024513824 A JP2024513824 A JP 2024513824A JP 2024513824 A JP2024513824 A JP 2024513824A JP WO2024029599 A5 JPWO2024029599 A5 JP WO2024029599A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharma
- acceptable salt
- total weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 229940126062 Compound A Drugs 0.000 claims 39
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 31
- 239000013078 crystal Substances 0.000 claims 12
- 238000005469 granulation Methods 0.000 claims 11
- 230000003179 granulation Effects 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 239000000843 powder Substances 0.000 claims 10
- 239000008187 granular material Substances 0.000 claims 9
- 238000002156 mixing Methods 0.000 claims 9
- 239000007884 disintegrant Substances 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 229950008138 carmellose Drugs 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- MUNWOYRHJPWQNE-GMFUQMJFSA-N dersimelagon Chemical compound C1(CCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H]([C@H](C1)COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O MUNWOYRHJPWQNE-GMFUQMJFSA-N 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000013112 stability test Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111432A JP2024138436A (ja) | 2022-08-03 | 2024-07-11 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022123712 | 2022-08-03 | ||
| JP2022123712 | 2022-08-03 | ||
| PCT/JP2023/028459 WO2024029599A1 (ja) | 2022-08-03 | 2023-08-03 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111432A Division JP2024138436A (ja) | 2022-08-03 | 2024-07-11 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2024029599A1 JPWO2024029599A1 (https=) | 2024-02-08 |
| JPWO2024029599A5 true JPWO2024029599A5 (https=) | 2024-07-09 |
| JP7527582B2 JP7527582B2 (ja) | 2024-08-05 |
Family
ID=89849491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513824A Active JP7527582B2 (ja) | 2022-08-03 | 2023-08-03 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
| JP2024111432A Pending JP2024138436A (ja) | 2022-08-03 | 2024-07-11 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111432A Pending JP2024138436A (ja) | 2022-08-03 | 2024-07-11 | １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250367122A1 (https=) |
| EP (1) | EP4566609A1 (https=) |
| JP (2) | JP7527582B2 (https=) |
| CN (1) | CN119654150A (https=) |
| WO (1) | WO2024029599A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609864UA (en) | 2014-05-29 | 2016-12-29 | Mitsubishi Tanabe Pharma Corp | Novel pyrrolidine compound and application as melanocortin receptor agonist |
| JP2017122056A (ja) * | 2016-01-05 | 2017-07-13 | 大原薬品工業株式会社 | 医薬含有造粒物の製造方法 |
| US12077524B2 (en) | 2018-12-28 | 2024-09-03 | Mitsubishi Tanabe Pharma Corporation | Crystal of pyrrolidine compound |
| MX2022015804A (es) * | 2020-06-10 | 2023-04-05 | Mitsubishi Tanabe Pharma Corp | Agente profilactico o terapeutico para porfiria. |
| KR20230016008A (ko) * | 2020-06-10 | 2023-01-31 | 미쓰비시 타나베 파마 코퍼레이션 | 광선성 피부질환의 예방 또는 치료제 |
-
2023
- 2023-08-03 CN CN202380056519.9A patent/CN119654150A/zh active Pending
- 2023-08-03 JP JP2024513824A patent/JP7527582B2/ja active Active
- 2023-08-03 EP EP23850152.2A patent/EP4566609A1/en active Pending
- 2023-08-03 US US19/099,877 patent/US20250367122A1/en active Pending
- 2023-08-03 WO PCT/JP2023/028459 patent/WO2024029599A1/ja not_active Ceased
-
2024
- 2024-07-11 JP JP2024111432A patent/JP2024138436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4084309B2 (ja) | 単一の結晶形を含有する固形製剤 | |
| JP5752227B2 (ja) | 口腔内崩壊錠 | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| JP7336388B2 (ja) | 錠剤及びその製造方法 | |
| JPH01165596A (ja) | 安定化された医薬物質、その製法および安定な医薬製剤 | |
| JPWO2009066773A1 (ja) | 口腔内崩壊錠 | |
| EP2162119A2 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
| JP6768984B2 (ja) | 酢酸亜鉛水和物錠及びその製造方法 | |
| TWI774159B (zh) | 含有托格列淨（Tofogliflozin）之固體製劑及其製造方法 | |
| JP5490347B2 (ja) | 経口投与用製剤 | |
| EP3648745B1 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
| JP2009524658A (ja) | レベチラセタム製剤、及びそれらの製造方法 | |
| JP7305527B2 (ja) | リバーロキサバンと嬌味剤を含有する固形製剤 | |
| JP5844574B2 (ja) | ピタバスタチンを含有する安定化された薬物組成物 | |
| JP7557291B2 (ja) | リナグリプチンと光安定化成分を含有する医薬製剤 | |
| JP2013216701A (ja) | 経口投与用製剤 | |
| JP2013203690A (ja) | 口腔内崩壊錠及びその製造方法 | |
| JPWO2024029599A5 (https=) | ||
| KR102206535B1 (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 | |
| WO2010027101A1 (ja) | 医療用固形製剤 | |
| JPH02286614A (ja) | アセトアミノフェン製剤 | |
| EP4534076A1 (en) | Celecoxib - acetaminophen combination of improved stability and procedure for the preparation thereof | |
| EA033685B1 (ru) | Фармацевтические лекарственные формы | |
| RU2221565C2 (ru) | Фармацевтическая композиция, обладающая противотуберкулезной активностью, и способ ее получения | |
| RU2207846C1 (ru) | Фармацевтическая твердая композиция, обладающая противотуберкулезным действием, и способ ее получения |